Full Committee Hearing: “Developments in the Prescription Drug Market: Oversight”

Invited Witnesses

Dr. Janet Woodcock    
Director, Center for Drug Evaluation and Research    
U.S. Food and Drug Administration    

Mr. Howard B. Schiller    
Interim Chief Executive Officer    
Valeant Pharmaceuticals International, Inc.    

Mr. Martin Shkreli    
Former Chief Executive Officer    
Turing Pharmaceuticals LLC    

Ms. Nancy Retzlaff    
Chief Commercial Officer    
Turing Pharmaceuticals LLC    

Mr. Mark Merritt    
President and Chief Executive Officer    
Pharmaceutical Care Management Association